Davita Healthcare Partners DVA

$174.07 -9.43 (-5.14%)

Valuation

Market cap
11,542,150,000
Revenue TTM
$13,643,070,000
Net income TTM
$746,800,000
P/E (trailing)
12.71
P/E (forward)
12.23
Profit margin
5.47%
Debt to equity
-30.19

Trading

Volume
834,710
Avg volume
752,914
Day's range
$174.01 – $182.00
Shares out
62,900,000
Stochastic %K
0%
Beta
0.87
Analysts
Moderate Buy
Price target
$225.86

Price

Company profile

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other phys...

Show more

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

Industry
Medical Care Facilities
Sector
Healthcare
Phone
720 631 2100
Website
https://www.davita.com
Address
2000 16th Street, Denver, United States

Latest news

Stocktwits

wolfofwestloop Nov 12, 5:30 PM
$CRMD I think it's pretty clear $DVA and the short seller are connected.
0 replies
Noname2022 Nov 10, 12:19 PM
$DVA $AKBA $CRMD https://stockanalysis.com/stocks/dva/transcripts/793404-ubs-global-healthcare-conference/
1 replies
Gencooliveoil Nov 9, 10:03 PM
$DVA $CRMD $AKBA
0 replies
Noname2022 Nov 9, 8:25 PM
$DVA $CRMD $AKBA https://stockanalysis.com/stocks/dva/transcripts/793404-ubs-global-healthcare-conference/
0 replies
GTA_Terminal Nov 7, 10:52 AM
Dark pool check on $DVA: what traded off the exchanges this session. The stock moved -1.8% on the day, so this wasn't happening in a quiet tape. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=DVA&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=DVA Read the full article for the full details: https://globaltradersacademy.com/articles/dark-pool-check-davita-dva?utm_source=stocktwits&utm_medium=social
0 replies
Noname2022 Nov 6, 11:15 PM
$AKBA $CRMD $DVA $FMS For those following policy & advocacy of KCAPA
1 replies
EZ_DUZ_IT Nov 5, 10:23 PM
$DVA Green in a sea of red 😬
0 replies
Noname2022 Nov 2, 1:47 PM
$DVA $CRMD “CorMedix has not provided the LDO or any other party with past or forecasted utilization or pricing data that would be necessary to estimate future quarterly adjustments to the 2027 Add-on. We believe any third-party projections regarding future quarterly adjustments are subject to significant uncertainty without visibility into the relevant utilization and pricing data. Investors should not interpret third-party projections as guidance provided or endorsed by CorMedix.” https://cormedix.com/cormedix-therapeutics-provides-business-update-reaffirms-2026-total-revenue-guidance-and-reports-third-quarter-cash-position/
2 replies